<unk>  is an alpha-galactosidase A (alpha-Gal A) pharmacological chaperone that is FDA approved for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.   Common adverse reactions include headache, nasopharyngitis, urinary tract infection, nausea, and pyrexia.
Migalastat
Cobicistat
Miglustat
Ketotifen
Olaflur
Eliglustat
Tiocarlide
Pemirolast